Abraxis' portfolio includes the world's first protein-based nanoparticle chemotherapeutic compound called nab Technology. From this the company has developed Abraxane, a treatment for metastatic breast cancer. On June 30, 2010, it was announced that Abraxis BioScience would be acquired by Celgene Corporation.
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|